Cancer vaccine trial for brain tumors pulled before it started
NCT ID NCT07199413
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This was a small, early-phase study designed to test the safety and feasibility of a cancer vaccine (SV-BR-1-GM) combined with the immunotherapy drug pembrolizumab (Keytruda) in patients with solid tumors that had spread to the brain or spinal cord lining. The trial planned to enroll adults whose brain metastases had worsened despite standard treatment. However, the study was withdrawn before any participants were enrolled, so no results are available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SV-BR-1-GM vaccine (a whole-cell vaccine that secretes GM-CSF), cyclophosphamide, pembrolizumab (Keytruda), and interferon (Sylatron)
- What this could lead to
- If it had worked, this could point toward a new way to treat brain metastases from solid tumors by using the immune system to attack cancer cells in the central nervous system.
- What could go wrong
- This trial was withdrawn before any patients were enrolled, so no data on safety or effectiveness exist. The combination of multiple drugs also raises the risk of serious side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRAIN METASTASES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Spinal injection of dual immunotherapy plus chemotherapy targets cancer spread to brain lining
- Can a 3D camera make brain radiation safer and more precise?
- Spinal fluid injection of Dual-Target antibody and chemotherapy shows promise for deadly cancer complication
- Smartwatch could alert doctors to brain cancer complications before they worsen
- Pinpoint radiation may spare the brain in lung cancer that spreads
- Spinal fluid DNA test could personalize brain cancer therapy